ECM
BIIB icon

ETrade Capital Management’s Biogen BIIB Stock Holding History

ETrade Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$869K Buy
3,064
+439
+17% +$122K 0.02% 411
2020
Q2 		$702K Sell
2,625
-356
-12% -$107K 0.01% 463
2020
Q1 		$943K Sell
2,981
-4,049
-58% -$1.23M 0.02% 304
2019
Q4 		$2.09M Buy
7,030
+25
+0.4% +$6.94K 0.05% 206
2019
Q3 		$1.63M Buy
7,005
+924
+15% +$215K 0.04% 241
2019
Q2 		$1.42M Buy
6,081
+746
+14% +$172K 0.04% 273
2019
Q1 		$1.26M Sell
5,335
-2,113
-28% -$665K 0.04% 278
2018
Q4 		$2.24M Sell
7,448
-185
-2% -$59K 0.07% 155
2018
Q3 		$2.7M Sell
7,633
-846
-10% -$291K 0.08% 149
2018
Q2 		$2.46M Buy
8,479
+843
+11% +$237K 0.08% 148
2018
Q1 		$2.09M Sell
7,636
-691
-8% -$214K 0.07% 172
2017
Q4 		$2.65M Buy
8,327
+314
+4% +$101K 0.09% 134
2017
Q3 		$2.51M Buy
8,013
+546
+7% +$162K 0.09% 132
2017
Q2 		$2.03M Buy
7,467
+66
+0.9% +$17.5K 0.08% 154
2017
Q1 		$2.02M Buy
7,401
+1,061
+17% +$300K 0.08% 150
2016
Q4 		$1.8M Buy
6,340
+1,715
+37% +$508K 0.08% 148
2016
Q3 		$1.45M Buy
4,625
+1,789
+63% +$530K 0.07% 169
2016
Q2 		$686K Buy
2,836
+1,020
+56% +$269K 0.04% 292
2016
Q1 		$473K Buy
1,816
+856
+89% +$226K 0.03% 335
2015
Q4 		$294K Buy
960
+217
+29% +$62.4K 0.02% 383
2015
Q3 		$217K Buy
743
+205
+38% +$67.7K 0.01% 401
2015
Q2 		$217K Buy
538
+8
+2% +$3.21K 0.01% 392
2015
Q1 		$224K Buy
+530
New +$209K 0.01% 372
2014
Q3 		– Sell
-650
Closed -$205K – 436
2014
Q2 		$205K Buy
650
+454
+232% +$137K 0.01% 411
2014
Q1 		$60K Sell
196
-1
-0.5% -$317 ﹤0.01% 545
2013
Q4 		$55K Sell
197
-12
-6% -$3.1K ﹤0.01% 465
2013
Q3 		$50K Buy
209
+18
+9% +$4.03K ﹤0.01% 428
2013
Q2 		$41K Buy
+191
New +$40.8K ﹤0.01% 401

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ETrade Capital Management's BIIB Position: Q3 2020 in Review

ETrade Capital Management increased its Biogen (BIIB) stake by 17% in Q3 2020, buying an estimated $122K and bringing the position to 3,064 shares worth $869K. The position accounts for 0.02% of the portfolio, ranked #411.

ETrade Capital Management first reported a position in BIIB in Q2 2013 and has held it in 28 quarters since. The position peaked at $2.7M in Q3 2018. 1,052 funds tracked by Wall St. Rank hold BIIB as of Q3 2020.

  • ETrade Capital Management held 3,064 shares of Biogen worth $869K as of Q3 2020.
  • ETrade Capital Management bought 439 Biogen shares in Q3 2020, an estimated $122K.
  • Biogen made up 0.02% of ETrade Capital Management's portfolio in Q3 2020, its #411 holding.
  • ETrade Capital Management first reported a position in Biogen in Q2 2013 and has held it in 28 quarters since.
  • ETrade Capital Management's Biogen position peaked at $2.7M in Q3 2018.
  • 1,052 funds tracked by Wall St. Rank held Biogen as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.